Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORMP 
Oramed Pharmaceuticals Inc (ORMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ORMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.25
1 Year Target Price $3.25
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.39% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 89.26M USD | Price to earnings Ratio - | 1Y Target Price 3.25 |
Price to earnings Ratio - | 1Y Target Price 3.25 | ||
Volume (30-day avg) 1 | Beta 1.19 | 52 Weeks Range 1.82 - 3.09 | Updated Date 11/5/2025 |
52 Weeks Range 1.82 - 3.09 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -683.65% |
Management Effectiveness
Return on Assets (TTM) -4.94% | Return on Equity (TTM) -14.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6042749 | Price to Sales(TTM) 45.92 |
Enterprise Value 6042749 | Price to Sales(TTM) 45.92 | ||
Enterprise Value to Revenue 3.02 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 39848233 | Shares Floating 32636815 |
Shares Outstanding 39848233 | Shares Floating 32636815 | ||
Percent Insiders 13.54 | Percent Institutions 18.26 |
Upturn AI SWOT
Oramed Pharmaceuticals Inc
Company Overview
History and Background
Oramed Pharmaceuticals Inc. was founded in 2006 and is based in New York. The company focuses on the development of oral drug delivery systems. A key milestone is their focus on an oral insulin capsule for diabetes treatment. They have evolved into a clinical-stage pharmaceutical company.
Core Business Areas
- Oral Insulin Development: Oramed is primarily focused on the development of an oral insulin capsule, ORMD-0801, as a potential treatment for diabetes. This is their lead product candidate.
- Oral GLP-1 Development: Oramed also developing an oral GLP-1 (Glucagon-Like Peptide-1) candidate, ORMD-0802.
Leadership and Structure
The leadership team includes Nadav Kidron (CEO). The company has a standard organizational structure with departments for research, development, clinical trials, and administration.
Top Products and Market Share
Key Offerings
- ORMD-0801 (Oral Insulin Capsule): This is Oramed's lead product candidate, an oral insulin capsule being developed for the treatment of Type 2 diabetes and potentially for Type 1 diabetes. It is currently in Phase 3 clinical trials. Market share data is not yet available as the product is not yet commercially available. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY) which have injectable and other diabetes treatments. Success would disrupt the insulin delivery market.
- ORMD-0802 (Oral GLP-1): This is Oramed's oral GLP-1 candidate, an oral GLP-1 under development for the treatment of Type 2 diabetes. It is currently in Phase 1 clinical trials. Market share data is not yet available as the product is not yet commercially available. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY) which have injectable and other GLP-1 treatments. Success would disrupt the GLP-1 delivery market.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the diabetes treatment market, is large and competitive. There is a growing demand for more convenient and effective diabetes management solutions. There is a large focus on GLP-1 agonists in the T2D market.
Positioning
Oramed is positioned as an innovative company aiming to disrupt the diabetes treatment market with its oral insulin and GLP-1 technology. Its competitive advantage lies in the potential convenience of oral delivery compared to injections.
Total Addressable Market (TAM)
The global diabetes market is estimated to be in the hundreds of billions of dollars. Oramed is positioned to capture a portion of this market if its oral insulin and GLP-1 therapies are successful.
Upturn SWOT Analysis
Strengths
- Novel oral drug delivery technology
- Potential to disrupt the diabetes treatment market
- Strong intellectual property portfolio
- Lead product candidate in Phase 3 trials
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
- High cash burn rate
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Growing demand for oral diabetes treatments
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent infringement
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly (LLY)
- Sanofi (SNY)
Competitive Landscape
Oramed is a small player compared to established pharmaceutical giants. Its advantage lies in its potentially disruptive oral delivery technology. Oramed faces risks relating to competition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development milestones rather than revenue growth.
Future Projections: Future growth depends on the successful commercialization of ORMD-0801. Analyst projections vary based on the perceived likelihood of regulatory approval and market adoption.
Recent Initiatives: Recent initiatives include the progression of ORMD-0801 through Phase 3 clinical trials and securing funding for continued development.
Summary
Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing oral drug delivery systems, primarily for diabetes. While the company's novel approach presents a significant opportunity to disrupt the market, it faces numerous challenges including clinical trial risks, funding requirements, and competition from larger pharmaceutical companies. The success of its oral insulin and GLP-1 candidates is crucial for its future growth. Oramed's lack of market share compared to large companies is a significant issue it must consider.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oramed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2006-04-21 | President, CEO & Executive Chairman Mr. Nadav Kidron Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.oramed.com |
Full time employees - | Website https://www.oramed.com | ||
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.